Funding for this research was provided by:
Fundación Fero (2015)
Fundación Científica Asociación Española Contra el Cáncer (JP Barcelona)
Instituto de Salud Carlos III (PI16/01371)
Received: 16 July 2019
Accepted: 31 January 2020
First Online: 5 February 2020
Ethics approval and consent to participate
: This study was approved by the Institutional Review Board from Vall d’Hebron University Hospital (#PR (AG)216/2015) and Sant Pau University Hospital (#25/2015). Written informed consent was obtained from all patients to donate blood samples and tumor tissue.
: Not applicable.
: C.S. has received research grants from Deciphera Pharmaceuticals, Bayer Healthcare and Pfizer, Inc.; consulting fees (advisory role) from Deciphera Pharmaceuticals and Blueprint Medicines; payment for lectures from Bayer Healthcare; and travel grants from Pharmamar, Pfizer, Bayer Healthcare, Novartis and Lilly. S.G. has not conflict of interest directly related to this manuscript, although the content is related to Blueprint Medicines, Deciphera Pharmaceuticals and AstraZeneca consulting fees/honorarium.